Vericel Corporation Insider Acquires Additional Shares
Chief Medical Officer Jonathan Mark Hopper purchases 5,000 shares of Vericel.
Key Points
- Jonathan Mark Hopper, Vericel's CMO, bought 5,000 shares on June 26, 2026, at $29.82 each, totaling $149,100.
- Vericel has a market cap of $2.27 billion, a P/E ratio of 103.5, and a 52-week range of $28.95 to $46.62.
- Analysts maintain a 'buy' rating with a mean price target of $55.43 across 7 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Jonathan Mark Hopper, the Chief Medical Officer of Vericel Corporation, bought 5,000 shares of the company. He purchased the shares at an average price of $29.82 each, bringing the total transaction to $149,100. This move was not part of a pre-planned 10b5-1 trading plan.
Insider Buying and Selling at Vericel Corporation
Other insider activities on the same day included Jonathan Siegal, Principal Accounting Officer, buying 2,500 shares at $29.82 each. Meanwhile, Sean Flynn, the Chief Legal Officer, bought 15,000 shares at $16.25 and sold the same amount at $45.64 under a planned transaction.
Other Institutional Activity in Vericel Corporation
Institutional investors have been active in Vericel Corporation. BlackRock, Inc. increased its holdings by 58,269 shares, ending with 7,765,344 shares valued at approximately $249.8 million. State Street Corp reduced its position by 11,792 shares to a total of 3,152,130 shares worth about $101.4 million. Soleus Capital Management, L.P. significantly boosted its stake by 1,785,079 shares, resulting in 2,549,079 shares valued at $82 million. Conestoga Capital Advisors, LLC added 208,750 shares, holding 2,463,312 shares valued at $79.2 million. Vanguard Capital Management LLC opened a new position with 2,230,756 shares valued at $71.8 million.
Vericel Corporation Stock Up 8.6%
As of Wednesday, shares of NasdaqGM:VCEL traded near $44.49. Vericel Corporation, with a market cap of approximately $2.27 billion, has a P/E ratio of 103.5 and a forward P/E of 52.2. The stock's 52-week range spans from $28.95 to $46.62, with a 50-day moving average of $36.28 and a 200-day moving average of $35.73. The company maintains a current ratio of 5.18 and a quick ratio of 4.62, with a debt-to-equity ratio of 26.68.
$VCEL stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Vericel reported revenue of $292.1 million, reflecting a growth rate of 30.1%. The company achieved a net margin of 7.3% and a return on equity of 6.6%. Earnings per share stood at $0.43. The next earnings report is scheduled for July 30, 2026.
Analysts Set New Price Targets
Analysts remain optimistic about Vericel's prospects. On April 15, 2026, Truist Securities maintained a 'buy' rating with a $42 price target. HC Wainwright & Co. also maintained a 'buy' rating with a $64 target on February 27, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $55.43 based on seven analyst opinions.
About Vericel Corporation
Vericel Corporation is a biopharmaceutical company based in Burlington, Massachusetts. It focuses on developing, manufacturing, and distributing cellular therapies and biologic products for sports medicine and severe burn care in North America. The company offers products like MACI for knee cartilage repair, Epicel for burn care, and NexoBrid for eschar removal. Vericel, led by CEO Dominick C. Colangelo, employs approximately 398 people.
Bottom Line
Jonathan Mark Hopper's purchase of Vericel shares highlights insider confidence in the company's future. Vericel's solid market position and positive earnings growth make it a company to watch. Keep in mind that insider transactions like these are reported after they occur and may not reflect the current position.
Get Vericel Corporation alerts
New 13F filings, insider trades, and analyst moves on $VCEL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.